Definition and Overview
Ibogaine is a naturally occurring indole alkaloid most closely associated with the root bark of Tabernanthe iboga, a shrub native to parts of Central Africa including Gabon and Cameroon.[1] It is commonly described as a psychedelic, but its effects differ from classic serotonergic psychedelics such as psilocybin or LSD because it acts across multiple receptor systems and produces a prolonged, dreamlike, dissociative, and physically demanding experience.[1][2]
In contemporary settings, ibogaine is best known for reports that it may interrupt opioid withdrawal and reduce drug craving after a single medically supervised administration.[3] It is not approved by the U.S. Food and Drug Administration for opioid-use disorder, traumatic brain injury, depression, PTSD, or any other medical indication, and its cardiac toxicity is a central barrier to mainstream clinical use.[2]
- Class: Atypical psychedelic and psychoactive indole alkaloid.[1]
- Primary source: Tabernanthe iboga root bark, though purified and synthetic forms also exist.[1]
- Main active metabolite: Noribogaine, formed largely through CYP2D6 metabolism and associated with longer-lasting post-acute effects.[3]
- Main medical concern: QT prolongation, hERG potassium-channel inhibition, torsades de pointes risk, and sudden cardiac death.[2]
For a general introduction, see What Is Ibogaine?; for the subjective experience, see Ibogaine Trip.[1]
History and Traditional Use
Iboga-containing preparations have long been used in Bwiti and related Central African religious contexts for initiation, healing, endurance, divination, and visionary experience.[1] The plant material is culturally distinct from isolated ibogaine hydrochloride because traditional use involves whole-plant preparations, ritual structure, community participation, and spiritual interpretation.[1]
Ibogaine was isolated from Tabernanthe iboga in the early twentieth century and later appeared in French pharmaceutical history as Lambarène, a preparation marketed for fatigue and related indications before being withdrawn from routine use.[1][2] Modern Western interest in ibogaine for addiction is commonly traced to Howard Lotsof, who reported in the 1960s that ibogaine reduced heroin craving and later pursued patents for addiction-related uses.[1]
Since the late twentieth century, ibogaine treatment has developed through a mixture of underground providers, private clinics, observational research, and limited regulated medical contexts rather than through broad approval as a standard medicine.[4] This mixed history helps explain why ibogaine is simultaneously discussed as a traditional sacrament, a psychedelic, an experimental addiction intervention, and a public-health controversy.[1][4]
Mechanism of Action
Ibogaine is pharmacologically complex and is better understood as a polypharmacological compound than as a single-receptor psychedelic.[1] It interacts with systems relevant to opioid signaling, glutamate transmission, serotonin transport, nicotinic acetylcholine receptors, sigma receptors, dopamine-related reward pathways, and cardiac ion channels.[1][2]
Ibogaine is metabolized in the liver into noribogaine, an active metabolite that persists longer than the parent compound and may contribute to sustained anti-craving, mood, and withdrawal-related effects.[3] Deborah Mash and colleagues emphasized that ibogaine pharmacokinetics and noribogaine exposure are central to understanding its clinical effects in drug dependence.[3]
- Opioid-related effects: Ibogaine and noribogaine interact with opioid systems, which may help explain reports of reduced opioid withdrawal, although ibogaine is not a conventional opioid agonist therapy like methadone or buprenorphine.[3]
- NMDA-glutamate modulation: Ibogaine has noncompetitive NMDA-antagonist properties, a mechanism that may contribute to dissociative and neuroplasticity-related effects.[1]
- Serotonin transporter activity: Noribogaine inhibits the serotonin transporter, which may contribute to prolonged mood and craving effects after the acute experience.[3]
- Nicotinic acetylcholine receptor effects: Ibogaine-related research has focused on nicotinic receptor subtypes implicated in reward and dependence, helping inspire non-classical analog development.[1]
- Neurotrophic signaling: A preclinical study reported that ibogaine increased glial cell line-derived neurotrophic factor, or GDNF, in the ventral tegmental area and reduced alcohol self-administration in rats.[5]
- Cardiac ion channels: Ibogaine inhibits hERG potassium channels, a mechanism strongly linked to QT prolongation and torsades de pointes risk.[2]
Because these mechanisms overlap with addiction, mood, perception, autonomic function, and cardiac electrophysiology, ibogaine’s potential benefits and risks arise from the same broad pharmacological profile.[1][2]
Psychedelic and Subjective Effects
Ibogaine commonly produces a long, oneirogenic experience, meaning that users may report dreamlike visions, autobiographical imagery, memory review, emotional processing, and altered perception while often remaining physically still for many hours.[1] The acute psychoactive period is often described as lasting roughly 12 to 24 hours, with residual stimulation, insomnia, ataxia, and psychologic